Regulation of RASSF1A in nasopharyngeal cells and its response to UV irradiation

Lee, Vien H.Y.; Chow, Billy K. C.; Lo, Kwok Wai; Chow, Lillian; Man, Cornelia; Tsao, Sai‐Wah; Lee, Leo Tsz On

doi:10.1016/j.gene.2009.05.003

Cited by 8 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, Sp1 usually activates transcription and Sp3 represses or most weakly activates transcription (Higgins et al, 2006;Jaiswal et al, 2006;Noe et al, 2001). Though in some studies it was shown that Sp1 and Sp3 synergistically enhanced gene promoter function, we have shown that Sp1 and Sp3 did not exist in the same protein complexes in the TFF1 promoter in MCF-7 cells (Hantusch et al, 2007;He et al, 2005;Lee et al, 2009;Li and Davie, 2008).…”

Section: Role Of Transcription Factors Sp1 and Sp3 In Breast Cancercontrasting

confidence: 54%

Metabolomics and Transcriptional Responses in Estrogen Receptor Positive Breast Cancer Cells

Mandal¹,

Khan²,

Li³

et al. 2011

Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways

View full text Add to dashboard Cite

Section: Role Of Transcription Factors Sp1 and Sp3 In Breast Cancercontrasting

confidence: 54%

Metabolomics and Transcriptional Responses in Estrogen Receptor Positive Breast Cancer Cells

Mandal¹,

Khan²,

Li³

et al. 2011

Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways

View full text Add to dashboard Cite

“…In particular, DNA methylation is a common mechanism for the inactivation or silencing of tumor-suppressor gene (TSG) or other functional genes in tumor cells. Epigenetic alterations by DNA methylation of CpG islands within the promoter regions of TSGs have been validated as important factors influencing the development and progression of many types of cancers (Lee et al, 2009). The exact diagnosis of kidney cancer during the early stages (for renal cancer treatment) has become possible through developments in imaging technology.…”

Section: Discussionmentioning

confidence: 99%

Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. Epigenetic inactivation of Ras-associated domain family 1A (RASSF1A) by hyper-methylation of its promoter region has been identified in various cancers. However, the role of RASSF1A in renal cancer has neither been thoroughly investigated nor reviewed. In this study, we reviewed and performed a meta-analysis of 13 published studies reporting correlations between methylation frequency of the RASSF1A promoter region and renal cancer risk. The odds ratios (ORs) of eligible studies and their corresponding 95% confidence intervals (95%CIs) were used to correlate RASSF1A promoter methylation with renal cell cancer risk and clinical or pathological variables, respectively. RASSF1A promoter methylation was significantly associated with the risk of renal cell cancer (OR = 19.35, 95%CI = 9.57-39.13). RASSF1A promoter methylation was significantly associated with pathological tumor grade (OR = 3.32, 95%CI = 1.55-7.12), and a possible positive correlation between RASSF1A promoter methylation status and tumor stage was noted (OR = 1.89, 95%CI = 1.00-3.56, P = 0.051). Overall, this meta-analysis demonstrated that RASSF1A promoter methylation is significantly associated with increased risk of renal cell cancer. RASSF1A promoter methylation frequency was positively correlated with pathological tumor grade, but not the clinical stage. This study showed that RASSF1A promoter methylation could be utilized to predict renal cell cancer prognosis.

show abstract

“…In EBV-mediated gastric carcinoma, EBV infection resulted in enhanced cell migration and invasion via increased FAK phosphorylation (Kassis et al 2002). Lastly, although the transcription factor SP3 itself has not been implicated in NPC, one of its target genes, RASSF1, is a tumor suppressor and plays an important role in NPC development (Lee et al 2009). Therefore MAML2, PTK2, and SP3 are candidate oncogenes that may act in a dominant fashion to help drive NPC tumor initiation or progression.…”

Section: Discussionmentioning

confidence: 99%

Discovery of recurrent structural variants in nasopharyngeal carcinoma

et al. 2013

View full text Add to dashboard Cite

We present the discovery of genes recurrently involved in structural variation in nasopharyngeal carcinoma (NPC) and the identification of a novel type of somatic structural variant. We identified the variants with high complexity mate-pair libraries and a novel computational algorithm specifically designed for tumor-normal comparisons, SMASH. SMASH combines signals from split reads and mate-pair discordance to detect somatic structural variants. We demonstrate a >90% validation rate and a breakpoint reconstruction accuracy of 3 bp by Sanger sequencing. Our approach identified three in-frame gene fusions (YAP1-MAML2, PTPLB-RSRC1, and SP3-PTK2) that had strong levels of expression in corresponding NPC tissues. We found two cases of a novel type of structural variant, which we call ''coupled inversion,'' one of which produced the YAP1-MAML2 fusion. To investigate whether the identified fusion genes are recurrent, we performed fluorescent in situ hybridization (FISH) to screen 196 independent NPC cases. We observed recurrent rearrangements of MAML2 (three cases), PTK2 (six cases), and SP3 (two cases), corresponding to a combined rate of structural variation recurrence of 6% among tested NPC tissues.

show abstract

Regulation of RASSF1A in nasopharyngeal cells and its response to UV irradiation

Cited by 8 publications

References 50 publications

Metabolomics and Transcriptional Responses in Estrogen Receptor Positive Breast Cancer Cells

Metabolomics and Transcriptional Responses in Estrogen Receptor Positive Breast Cancer Cells

Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis

Discovery of recurrent structural variants in nasopharyngeal carcinoma

Contact Info

Product

Resources

About